How many drugs treat Impotence?

Drug Landscape tracks 8 marketed treatments for Impotence (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/impotence.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Impotence — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impotence (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Impotence, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Stendra	AVANAFIL	Vivus Llc	Phosphodiesterase 5 Inhibitor [EPC]	cGMP-specific 3',5'-cyclic phosphodiesterase	2012-01-01
Viagra	sildenafil	Pfizer Inc.	PDE5 inhibitor	Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, Multidrug resistance-associated protein 5	1998-03-27
Caverject	ALPROSTADIL	Pfizer	Prostaglandin Analog [EPC]	Prostaglandin E2 receptor EP3 subtype	1981-01-01
Revatio	Sildenafil Citrate	Pfizer Inc.	PDE5 inhibitor	Phosphodiesterase type 5 (PDE5)
Cialis	Cialis	Ottawa Hospital Research Institute		Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2
Levitra	Levitra	Rabin Medical Center		Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
Cialis	tadalafil	Eli Lilly	Phosphodiesterase 5 Inhibitor [EPC]	Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2
Prostavasin	Prostavasin	Hannover Medical School		Cation channel sperm-associated protein 1, Cation channel sperm-associated protein 2, Cation channel sperm-associated protein 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer Inc. · 2 drugs in Impotence
· 2 drugs in Impotence
Hannover Medical School · 1 drug in Impotence
Ottawa Hospital Research Institute · 1 drug in Impotence
Pfizer · 1 drug in Impotence
Rabin Medical Center · 1 drug in Impotence
Vivus Llc · 1 drug in Impotence
Eli Lilly · 1 drug in Impotence

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Impotence:

Cite this brief

Drug Landscape (2026). Impotence — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/impotence. Accessed 2026-06-10.

Impotence full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing